Insights On Facility Design

1. Demonstrating ROI For Increased Digital Plant Maturity 4/28/2022

   Cytiva has partnered with the independent software company, Biopharm Services (BPS), to model the costs and associated benefits of increasing digital maturity for monoclonal antibody processes in a biopharma plant utilizing single-use technology.

2. Accelerator℠ Vision Platform 3/11/2022

   The Pall Accelerator Vision Platform gives you the ability to create virtual replicas of process equipment displayed in your manufacturing facility.

3. Cleanliness Is Next To Godliness In The Manufacture Of Medicinal Products 2/23/2022

   Cleanrooms are used extensively in the pharmaceuticals, biotech, medical device, and life sciences industries to reduce particulate contamination and to control other environmental parameters, including temperature, humidity, and pressure.

4. Never Too Early To Plan For Automation 2/22/2022

   Early platform design selections can greatly affect your future automation flexibility and ability to show compliance throughout regulatory reviews.

5. The Impact Of Facility Design On The Safety Of Viral Vectors 2/18/2022

   It is critical to vet not just the expertise available at a CDMO, but also the effectiveness of their facility design to reduce risk and meet scale-up needs.

6. In-House Manufacturing: Key To Driving A Diabetes Vaccine? 1/28/2022

   Increasing constraints on today’s supply chain from the COVID-19 pandemic mean drug companies must secure strategies that can ensure product delivery in the face of these challenges.

7. Enabling Bioprocess Control With Successful Automation Strategies 12/9/2021

   In a recent live event with Bioprocess Online, industry experts at various stages of their automation journey discussed their approach to enhancing quality control and data integrity through automated technologies.

8. Biopharmaceuticals Development And Manufacturing: Wide-Ranging Expertise And Vertically Integrated Service 11/17/2021

   The company’s wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art cGMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing.

9. Modular Facilities - The Proven Response For Rapid Biomanufacturing Anywhere 9/28/2021

   Select one of the flexible, prefabricated cGMP biomanufacturing environment with a configurable production line that future-proofs capacity expansion, improves operational efficiency and minimizes infrastructure to begin manufacturing faster for a fraction of the cost.

10. Increasing mRNA Capabilities, Capacity 9/20/2021

    The growing mRNA vaccine market ― projected to reach $127.3 billion by 2027 ― is fueling high demand for mRNA, which has resulted in a critical need to address mRNA manufacturing bottlenecks.